title: Rosiglitazone therapy of posttransplant diabetes mellitus.
abstract: BACKGROUND
  The new onset of posttransplant diabetes mellitus (PTDM) is a common problem after solid organ transplantation. Because insulin resistance plays a significant role in the development of PTDM, we treated 40 consecutive patients with PTDM after liver and kidney transplantation with the insulin sensitizer rosiglitazone (ROSI).
  
  
  METHODS
  Thirty-three of 40 patients with PTDM were initially stabilized with twice-daily NPH and regular insulin. All patients subsequently began ROSI 4 mg per day. Patients were followed for a mean of 26 weeks and insulin was adjusted using home blood glucose data and hemoglobin A1C (HBA1C).
  
  
  RESULTS
  During 12 months of study, 32/107 liver transplant patients (30%) and 8/205 kidney transplant patients (4%) patients developed PTDM. After 3-4 months of insulin and ROSI therapy, insulin was able to be discontinued in 30/33 (91%) patients with PTDM. In all, 12/40 (30%) patients maintained normal HBA1C levels (5.6+/-0.8%) with ROSI monotherapy, whereas 25/40 (63%) required ROSI and a sulfonylurea to meet this goal. Three of 40 (7.5%) had persistent insulin dependence. 25/40 (63%) continued on 4 mg/day of ROSI, and 15/40 (37%) required an increase to 8 mg/day. Mild edema developed in 13% of patients; significant weight gain did not occur.
  
  
  CONCLUSIONS
  Rosiglitazone is the first highly effective oral agent for PTDM. The majority of patients with PTDM may be safely treated with ROSI +/- a sulfonylurea. After the expected 3-6 week delay in the onset of ROSI action, most patients with PTDM will no longer require long-term insulin therapy.
authors.affiliation: Section of Endocrinology, Rush University Medical Center, Chicago, IL 60612, USA.
authors.forename: Griselda
authors.initials: G
authors.lastname: Villanueva
authors.forename: David
authors.initials: D
authors.lastname: Baldwin
mesh_terms: D000328:Adult; D000368:Aged; D016572:Cyclosporine / Q000008:administration & dosage; D003924:Diabetes Mellitus, Type 2 / Q000139:chemically induced* / Q000188:drug therapy*; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007328:Insulin / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000009:adverse effects; D016031:Liver Transplantation / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D016377:Organ Transplantation / Q000009:adverse effects*; D047495:PPAR gamma / Q000819:agonists; D011446:Prospective Studies; D000077154:Rosiglitazone; D016559:Tacrolimus / Q000008:administration & dosage; D045162:Thiazolidinediones / Q000627:therapeutic use*
chemical_list: D016572:Cyclosporine; D006442:Glycated Hemoglobin; D007328:Insulin; D047495:PPAR gamma; D000077154:Rosiglitazone; D016559:Tacrolimus; D045162:Thiazolidinediones